This $1,200 Stock Could Be the Next Massive Stock Split Opportunity
Eli Lilly (LLY) reported Q1 2026 results showing Mounjaro revenue of $8.662 billion, up 125% year over year, and group incretin franchise revenue of $19.799 billion. The company raised full-year 2026 revenue guidance to $82 billion to $85 billion. LLY shares rose about 14% after earnings and traded near $1,200.
How this was made
The 30-second read
Why it matters
For trading, the actionable element is the combination of reported Q1 growth (Mounjaro and Zepbound) plus upward full-year guidance and a cited FDA approval of Foundayo, which can sustain momentum and re-rate expectations.
Market read
LLY’s reported Q1 strength and raised guidance are the main catalysts supporting continued bullish positioning, while the stock-split angle is narrative rather than a disclosed corporate action.
What to watch
The article notes realized prices fell 13% and volume rose 65%, so margin durability depends on pricing power and mix, not just unit growth.
Background
The piece argues LLY’s high share price is approaching “stock split territory,” using Q1 2026 product performance and raised full-year guidance as the core evidence.
Ticker impact
Article cites LLY Q1 2026 results, including Mounjaro revenue of $8.662B and raised full-year guidance to $82B-$85B.
Near-term bias remains positive while traders anchor to raised guidance and GLP-1 pill approval momentum; split expectations may add volatility.
The text provides specific, attributable financial datapoints (product revenue, EPS beat, guidance ranges) and a named FDA approval, but it does not disclose an actual board decision to split.
Market effects
Reinforces bullish read-through for GLP-1/incretin demand and large-cap pharma growth expectations.
Primarily US large-cap sentiment, with relative outperformance versus SPY and QQQ mentioned.
Supports global investor appetite for obesity/diabetes franchise leaders, though no international regulatory or market-specific facts are added.
Counterpoint
Stock-split framing may be speculative; traders could fade the narrative if guidance growth decelerates or if realized price declines persist.
Key entities
- companyEli Lilly
Subject of the article, with Q1 2026 product revenue, EPS beat, and raised 2026 guidance cited.
- productMounjaro
Cited as generating $8.662B in Q1 2026, up 125% YoY.
- productZepbound
Cited as generating $4.160B in the same quarter, up 80% YoY.
- productFoundayo
Cited as receiving U.S. FDA approval, described as a GLP-1 pill without food and water restrictions.
